Petosemtamab
Petosemtamab Basic information
- Product Name:
- Petosemtamab
- Synonyms:
-
- Petosemtamab
- Research Grade Petosemtamab (DHB86918)
- MCLA 158
- Research Grade Petosemtamab
- CAS:
- 2213450-26-9
- MW:
- 0
- Mol File:
- Mol File
Petosemtamab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Petosemtamab Usage And Synthesis
Uses
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2].
in vivo
MCLA-158 (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2].
| Animal Model: | Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2] |
| Dosage: | 25 mg/kg/week |
| Administration: | Intravenous injection (i.v.) for 6 weeks. |
| Result: | Inhibited tumor growth. |
IC 50
EGFR: 0.22 nM (Kd); LGR5: 0.85 nM (Kd)
References
[1] Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.
[2] Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl
PetosemtamabSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com